Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

The most prevalent symptom of discontinuation was dizziness, and, despite being measured in people with major depressive disorder, discontinuation was not associated with depression symptoms.